Continuous subcutaneous insulin infusion (CSII) has been studied as a possible therapy for type 2 diabetes (T2DM) for over 30 years, which helps to rapidly reduce hyperglycemic toxicity and improve patient outcomes, and is one of the important means of short-term insulin-intensive therapy. The gene discussed is INS; the disease is type 2 diabetes mellitus.